Brokerages Anticipate Chimerix, Inc. (CMRX) Will Announce Quarterly Sales of $810,000.00
Wall Street brokerages predict that Chimerix, Inc. (NASDAQ:CMRX) will announce sales of $810,000.00 for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Chimerix’s earnings, with estimates ranging from $500,000.00 to $1.00 million. Chimerix posted sales of $650,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 24.6%. The business is scheduled to report its next quarterly earnings results on Monday, November 6th.
On average, analysts expect that Chimerix will report full-year sales of $810,000.00 for the current financial year, with estimates ranging from $1.75 million to $4.43 million. For the next fiscal year, analysts expect that the company will report sales of $3.75 million per share, with estimates ranging from $1.00 million to $6.25 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Chimerix.
Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.05. The firm had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $1.28 million. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%.
A number of research firms have recently weighed in on CMRX. ValuEngine lowered Chimerix from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Wednesday, August 9th.
ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/10/01/brokerages-anticipate-chimerix-inc-cmrx-will-announce-quarterly-sales-of-810000-00.html.
A number of large investors have recently bought and sold shares of CMRX. Redmile Group LLC increased its holdings in Chimerix by 29.3% in the first quarter. Redmile Group LLC now owns 4,325,055 shares of the biopharmaceutical company’s stock valued at $27,594,000 after buying an additional 979,096 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Chimerix by 114.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,043,336 shares of the biopharmaceutical company’s stock valued at $6,656,000 after buying an additional 557,927 shares during the last quarter. Morgan Stanley increased its holdings in Chimerix by 203.9% in the first quarter. Morgan Stanley now owns 618,074 shares of the biopharmaceutical company’s stock valued at $3,944,000 after buying an additional 414,717 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Chimerix in the first quarter valued at $1,975,000. Finally, Vanguard Group Inc. increased its holdings in Chimerix by 13.1% in the first quarter. Vanguard Group Inc. now owns 1,848,257 shares of the biopharmaceutical company’s stock valued at $11,792,000 after buying an additional 213,894 shares during the last quarter. 67.53% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Chimerix (NASDAQ CMRX) opened at 5.25 on Friday. The firm’s market cap is $246.99 million. The stock has a 50 day moving average price of $4.72 and a 200-day moving average price of $5.27. Chimerix has a 52-week low of $3.66 and a 52-week high of $6.64.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related stocks with our FREE daily email newsletter.